Non-invasive BTL treatment made in Europe: FDA-cleared ultrasound plus monopolar RF to stimulate collagen and elastin around the eyes, firm skin, soften lines and slow periocular ageing.

The new fourth-generation BTL EXILIS Ultra 360 is a non-invasive treatment developed by BTL in the UK and manufactured in Europe. It uses the world’s only FDA-certified combination of ultrasound and monopolar radiofrequency technology to stimulate collagen and elastin production in the deeper periocular tissue, firming the eye-area skin, intercepting periocular ageing, strengthening support in the subcutaneous tissue under the eyes to smooth eye lines, restoring smoothness and firmness, and reversing the apparent age of the eyes.
Accelerates periocular circulation and improves puffiness; thickens the collagen protective layer to conceal blood vessels; fades dark circles; smooths eye lines; lifts the eye contour; and restores a youthful look.
BTL Exilis Ultra 360 ultra-frequency technology can penetrate to the deeper periocular tissue. During treatment the eye area will feel heat; the warmth helps the periocular area feel soothed and relaxed.
Noticeable firming and lifting can already be seen after one session. Completing 4 sessions within four weeks is recommended for better maintenance results.
The world’s only combination of monopolar radiofrequency and ultrasound technology. Energy penetrates the deeper layers of the skin in 360 degrees, distributed evenly, reaching every inch of periocular skin to stimulate collagen and elastin production and activate twice the collagen. Comfortably addresses four major periocular concerns: lifting, firming, fading dark circles, and increasing support under the eyes to intercept the formation of eye bags. Non-invasive, painless, with no downtime and lasting results; make-up may be applied immediately after treatment.
Laxity, fine lines, dark circles and mild under-eye droop.
Mild heat only; non-invasive with little discomfort.
Yes — typically no downtime.
Results may show after one; four sessions in four weeks are often advised.
FDA-cleared technology from BTL, manufactured in Europe; non-invasive.